BTK INHIBITOR / TARGETED THERAPY / ORAL

NCODA BRAND RESOURCE HUB

BRUKINSA®

(zanubrutinib)

BRAND PRONUNCIATION

broo · KIN · suh

GENERIC PRONUNCIATION

ZAN · yoo · BROO · tih · nib

MANUFACTURER

BeOne Medicines

Formerly BeiGene

DISEASE STATE FOCUS

CLL/SLL

Chronic lymphocytic leukemia / small lymphocytic lymphoma

MCL

Mantle cell lymphoma

MZL

Marginal zone lymphoma

WM

Waldenström’s macroglobulinemia

FL

Follicular lymphoma

CYCLE

28

Patient Treatment Calendars

Give patients a printable day-by-day schedule for their BRUKINSA regimen, with dose reminders and space for notes between visits.

 RESOURCE

Positive Quality Interventions

Peer-reviewed clinical guidance on patient selection and management, plus PQI in Action documents showing how practices put it to work.

Browse all NCODA PQIs →

PQI

POSITIVE QUALITY INTERVENTION

PQI

PQIiA

PQIiA

PQI IN ACTION

PQI IN ACTION

RESOURCE

Treatment Discussion Guide & Patient Education Sheets

A medically integrated framework for discussing BRUKINSA therapy across all five indications, with the matching Patient Education Sheets.

TDG

TREATMENT DISCUSSION GUIDE

PATIENT EDUCATION SHEET

PES

PATIENT EDUCATION SHEET

VIDEO SERIES · 8 EPISODES

CLL APP Video Series

Microlearning videos under 10 minutes each, built for advanced practice providers, oncology pharmacists and multidisciplinary teams.

Watch the full series →

CLL APP VIDEO SERIES · UNDER 10 MIN

WEBINAR SERIES · 3 PARTS

Step Edit Webinar Series

What step edits are, how they affect practices and patients, and how to navigate them. Recordings open in the NCODA member portal.

ON DEMAND

Webinars & Indication Videos

Side-effect management webinars and short videos on BRUKINSA in each approved indication.

PRACTICE TOOLS

White Papers & Toolkits

Guidance for BTK inhibitor selection, newly diagnosed CLL, and building CLL care into Epic.

EVIDENCE

Research & Publications

Real-world data presented by NCODA members, and the publications where it appears.